Company Overview and News

21
Market Live: Sell-off continues on trade tensions; all sectoral indices in the red

2018-06-19 moneycontrol
Oil Prices Update: Oil prices fell nearly one percent as an escalating trade dispute between the United States and China triggered sharp selloffs in many global markets.
LIBERTSHOE 523768 500325 GOACARBON GUJBOROS RELIANCE GLKQY 539437 500470 IDFCBANK RIGD 500790 NSZTY RLNIY 509567 SBAZ GLENMARK IBN 502219 TATAPOWER NESTLEIND HEXAWARE 539302 532129 POWERMECH BOROSIL ICICIBANK TTST 532296 TATASTEEL TATLY 532174 TPCL 500400 526596

36
Market Live: Sensex extends losses amid trade war woes; IOC, HPCL, BPCL dip 3%

2018-06-19 moneycontrol
Glenmark Pharmaceuticals announced that the US Food & Drug Administration provided its first supplemental abbreviated new drug application (sANDA) approval for the company’s manufacturing facility in Monroe, North Carolina.
LIBERTSHOE 523768 500325 GUJBOROS RELIANCE KAJARIACER 532418 BHRQY GLKQY 532215 JUSTDIAL CMQMY 500470 535648 533407 AXISBANK RIGD 500233 CUMMINSIND BHARTIARTL 500790 NSZTY RLNIY SBAZ GLENMARK AXB 502219 IBN NESTLEIND HEXAWARE 539302 532129 AXBKY POWERMECH 532454 BOROSIL AXBA 500480 ICICIBANK TTST 532296 TATASTEEL TATLY 532174 CNOVAPETRO 526596 JSTQY ANDHRABANK

2
Liberty Shoes Limited - Clarification - Financial Results

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
LIBERTSHOE 526596

2
Liberty Shoes Limited - News Clarification

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
LIBERTSHOE 526596

2
Liberty Shoes Limited - Outcome of Board Meeting

2018-03-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
LIBERTSHOE 526596

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...